September 16, 2020
Daiichi Sankyo has kickstarted a global PII clinical study of its HER3 directed DXd antibody drug conjugate (ADC) patritumab deruxtecan (U3-1402) in previously treated patients with HER3 expressing advanced/metastatic colorectal cancer. The PII study will assess the safety and efficacy...read more